This new information has not increased the quality of evidence for comparison of a longer vs a shorter, time-limited course of anticoagulation in patients without cancer. In patients with a rst proximal DVT or PE and active cancer who had residual DVT on US imaging after completing 6 months of LMWH therapy, the Cancer- Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study randomized patients to another 6 months of LMWH or to stop therapy and followed patients for 12 months after they stopped The additional 6 months of LMWH reduced recurrent VTE but, once anticoagulation was stopped, the risk of recurrent VTE was the same in those who had TABLE 11 ] Risk Factors for Bleeding with Anticoagulant Therapy and Estimated Risk of Major Bleeding in Low-, Moderate-, and High-Risk categoriesa Risk Factorsb Poor anticoagulant control189,196,203 Comorbidity and reduced functional capacity191,196,204 Nonsteroidal anti-in ammatory drug210 Categorization of Risk of Bleedingd Estimated Absolute Risk of Major Bleeding Low Riske Factors) Moderate Riske Factor) High Riske Factors) Anticoagulation Increased risk (%) Total risk (%) 1.6g Anticoagulation after rst 3 mof Baseline risk (%/y) 0.3i Increased risk (%/y) Total risk (%/y) 0.8j AT9 9th Edition of the Antithrombotic Guideline. a From AT9. Since AT9, references for bleeding with individual factors have ; nonsteroidal anti-in ammatory drug has been added as a risk factor; a systematic review has described the risk in VTE trial patients who were randomized to no antithrombotic therapy211 ; and several recent publications have compared clinical prediction rules for bleeding in various populations.193,212-216 b Most studies assessed risk factors for bleeding in patients who were on VKA therapy. The risk of bleeding with different anticoagulants is not addressed in this table. 